Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Withdraws Complete Genomics Bid

NEW YORK (GenomeWeb News) — Illumina has withdrawn its offer to acquire Complete Genomics, according to a filing submitted to the US Securities and Exchange today.

According to the filing, Illumina has also notified the Federal Trade Commission that it is withdrawing a Hart-Scott-Rodino merger prenotification filing related to the proposed acquisition.

Illumina made an unsolicited bid for Complete Genomics last November, offering $3.30 per share for the company — a bid 5 percent above that of BGI-Shenzhen, which in September offered approximately $118 million for the sequencing services firm.

Yesterday, BGI and Complete Genomics announced that the FTC had granted early termination of the Hart-Scott-Rodino waiting period for their proposed merger.

Illumina's proposal, meantime, was the subject of several information requests from the FTC. Complete Genomics had cited the fact that the agreement would not receive antitrust clearance as a key factor in rejecting Illumina's bid.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.